Good-To The Moon - Tiger Brokers Online Investing Community

2
Comment
Favorite

Catchua
2022-04-08

Good

Why Pfizer Stock Jumped 4% Thursday

Pfizer's planned acquisition of ReViral appears to be a smart move.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

Gabriel林倡銘
·2022-04-08
Yes
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9015064095,"tweetId":"9015064095","gmtCreate":1649393872923,"gmtModify":1676534505343,"author":{"id":3579261515703347,"authorId":3579261515703347,"authorIdStr":"3579261515703347","name":"Catchua","avatar":"https://static.tigerbbs.com/28615a1f839b67febc33928525f76b74","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Good&nbsp;</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9015064095","repostId":2225751106,"repostType":4,"repost":{"id":"2225751106","pubTimestamp":1649388452,"share":"https://www.laohu8.com/m/news/2225751106?lang=&edition=full","pubTime":"2022-04-08 11:27","market":"us","language":"en","title":"Why Pfizer Stock Jumped 4% Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2225751106","media":"Motley Fool","summary":"Pfizer's planned acquisition of ReViral appears to be a smart move.","content":"<html><head></head><body><h2>What happened</h2><p>Shares of <b>Pfizer</b> jumped 4.3% as of closing on Thursday while the major market indexes were declining. The gain came after the big drugmaker announced plans to buy privately held ReViral for up to $525 million.</p><h2>So what</h2><p>Investors appeared to view the acquisition of ReViral as a great fit for Pfizer. ReViral&#39;s pipeline features sisunatovir, an experimental oral therapy for treating respiratory syncytial virus (RSV) infection. ReViral is currently evaluating sisunatovir in two phase 2 studies targeting RSV in adults and infants.</p><p>Pfizer hopes to win regulatory approvals in the not-too-distant future for its RSV vaccine candidate PF-06928316. The experimental vaccine is in late-stage testing. Annaliesa Anderson, chief scientific officer for Pfizer&#39;s bacterial vaccines and hospital unit, said, &#34;The proposed acquisition of ReViral&#39;s pipeline of therapeutic candidates is complementary to our efforts to advance the first vaccine candidate to help protect against this harmful disease.&#34;</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a43e276882b50548e1a79eea5c5d299f\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><p>It&#39;s likely that investors also applauded the structure of the deal. Pfizer isn&#39;t paying $525 million upfront to buy ReViral. Instead, the total amount includes payments that hinge on the successful completion of key development milestones. This reduces Pfizer&#39;s risk with the transaction. Pfizer believes that ReViral&#39;s programs have the potential to generate at least $1.5 billion in peak sales.</p><h2>Now what</h2><p>Pfizer must now secure regulatory approvals for the acquisition of ReViral. With the nice move for the big pharma stock today, there are clear expectations of a smooth path to closing the deal. It won&#39;t be surprising if Pfizer makes additional acquisitions this year with the company&#39;s cash stockpile surging due to its COVID-19 program revenue.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer Stock Jumped 4% Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer Stock Jumped 4% Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-08 11:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/04/07/why-pfizer-stock-is-rising-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedShares of Pfizer jumped 4.3% as of closing on Thursday while the major market indexes were declining. The gain came after the big drugmaker announced plans to buy privately held ReViral ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/04/07/why-pfizer-stock-is-rising-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4581":"高盛持仓","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","PFE":"辉瑞","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2022/04/07/why-pfizer-stock-is-rising-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2225751106","content_text":"What happenedShares of Pfizer jumped 4.3% as of closing on Thursday while the major market indexes were declining. The gain came after the big drugmaker announced plans to buy privately held ReViral for up to $525 million.So whatInvestors appeared to view the acquisition of ReViral as a great fit for Pfizer. ReViral's pipeline features sisunatovir, an experimental oral therapy for treating respiratory syncytial virus (RSV) infection. ReViral is currently evaluating sisunatovir in two phase 2 studies targeting RSV in adults and infants.Pfizer hopes to win regulatory approvals in the not-too-distant future for its RSV vaccine candidate PF-06928316. The experimental vaccine is in late-stage testing. Annaliesa Anderson, chief scientific officer for Pfizer's bacterial vaccines and hospital unit, said, \"The proposed acquisition of ReViral's pipeline of therapeutic candidates is complementary to our efforts to advance the first vaccine candidate to help protect against this harmful disease.\"Image source: Getty Images.It's likely that investors also applauded the structure of the deal. Pfizer isn't paying $525 million upfront to buy ReViral. Instead, the total amount includes payments that hinge on the successful completion of key development milestones. This reduces Pfizer's risk with the transaction. Pfizer believes that ReViral's programs have the potential to generate at least $1.5 billion in peak sales.Now whatPfizer must now secure regulatory approvals for the acquisition of ReViral. With the nice move for the big pharma stock today, there are clear expectations of a smooth path to closing the deal. It won't be surprising if Pfizer makes additional acquisitions this year with the company's cash stockpile surging due to its COVID-19 program revenue.","news_type":1},"isVote":1,"tweetType":1,"viewCount":290,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":101106734,"gmtCreate":1649420207552,"gmtModify":1663246394147,"authorId":3575234021908444,"author":{"id":3575234021908444,"authorId":3575234021908444,"name":"Gabriel林倡銘","avatar":"https://community-static.tradeup.com/news/5f79fe34fb45208de204a36457e2a3d7","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9015064095,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}